QUANTITATIVE RISK-BENEFIT ANALYSIS OF ORAL PHOSPHODIESTERASE TYPE 5 INHIBITORS ON ERECTILE DYSFUNCTION TREATMENT

被引：0
|
作者：
Hsu, J. C. [1 ]
Tang, D. [2 ]
机构：
[1] Natl Cheng Kung Univ, Taipei, Taiwan
[2] Univ Arizona, Tucson, AZ USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1467
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A283 / A283
页数：1
相关论文
共 50 条
  • [31] Phosphodiesterase inhibitors in the treatment of erectile dysfunction
    Truss, MC
    Stief, CG
    [J]. DRUGS OF TODAY, 1998, 34 (09): : 805 - 812
  • [32] Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction
    Mulhall, JP
    Montorsi, F
    [J]. EUROPEAN UROLOGY, 2006, 49 (01) : 30 - 37
  • [33] Phosphodiesterase type 5 inhibitors’ extended duration of response as a variable in the treatment of erectile dysfunction
    M E Dunn
    S E Althof
    M A Perelman
    [J]. International Journal of Impotence Research, 2007, 19 : 119 - 123
  • [34] Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study
    Hatzichristou, D.
    Haro, J. M.
    Martin-Morales, A.
    von Keitz, A.
    Riley, A.
    Bertsch, J.
    Belger, M.
    Wolka, A. M.
    Beardsworth, A.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (11) : 1850 - 1862
  • [35] Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
    Ferguson, James E., III
    Carson, Culley C., III
    [J]. ARAB JOURNAL OF UROLOGY, 2013, 11 (03) : 222 - 229
  • [36] Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction
    Dunn, M. E.
    Althof, S. E.
    Perelman, M. A.
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2007, 19 (02) : 119 - 123
  • [37] A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
    Yuan, Jin-Qiu
    Mao, Chen
    Yang, Zu-Yao
    Fu, Xiao-Hong
    Wong, Samuel Y.
    Tang, Jin-Ling
    [J]. ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (01) : 60 - 65
  • [38] Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children
    Magee, Alan G.
    Makhecha, Sukeshi
    Bentley, Sian
    [J]. EXPERT OPINION ON DRUG SAFETY, 2015, 14 (05) : 633 - 642
  • [39] Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction
    Briganti, A
    Salonia, A
    Deho', F
    Zanni, G
    Barbieri, L
    Rigatti, P
    Montorsi, F
    [J]. WORLD JOURNAL OF UROLOGY, 2005, 23 (06) : 374 - 384
  • [40] Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction
    Alberto Briganti
    Andrea Salonia
    Federico Deho’
    Giuseppe Zanni
    Luigi Barbieri
    Patrizio Rigatti
    Francesco Montorsi
    [J]. World Journal of Urology, 2005, 23 : 374 - 384
12345